{"id":"avtx-002","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4303334","moleculeType":"Small molecule","molecularWeight":"612.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AVTX-002 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes.","oneSentence":"AVTX-002 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:08.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05288504","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.","status":"COMPLETED","sponsor":"Avalo Therapeutics, Inc.","startDate":"2022-02-24","conditions":"Non-Eosinophilic Asthma","enrollment":91},{"nctId":"NCT03169894","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Avalo Therapeutics, Inc.","startDate":"2017-07-14","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CERC-002, AEVI-002, MDGN-002"],"phase":"phase_2","status":"active","brandName":"AVTX-002","genericName":"AVTX-002","companyName":"Avalo Therapeutics, Inc.","companyId":"avalo-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AVTX-002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}